Percutaneous coronary interventions (PCIs) to treat multivessel coronary artery disease (MVCAD) may involve single-vessel or multivessel interventions, performed in one or more stages. This consensus statement reviews factors that may influence choice of strategy and includes six recommendations to guide decisions regarding staging of PCI [1]. Every patient who undergoes PCI should receive optimal therapy for coronary disease, ideally before starting the procedure [2]. Multivessel PCI at the time of diagnostic catheterization should be considered only if informed consent included the risks and benefits of multivessel PCI and the risks and benefits of alternative treatments [3]. When considering multivessel PCI, the interventionist should develop a strategy regarding which stenoses to treat or evaluate, and their order, method, and timing. This strategy should maximize patient benefits, minimize patient risk, and consider the factors described in this article [4]. For planned multivessel PCI, additional vessel(s) should be treated only if the first vessel is treated successfully and if anticipated contrast and radiation doses and patient and operator conditions are favorable [5]. After the first stage of the planned multistage PCI, the need for subsequent PCI should be reviewed before it is performed [6]. Third party payers and quality auditors should recognize that multistage PCI for MVCAD is neither an indication of poor quality nor an attempt to increase reimbursement when performed according to recommendations in this article. Published on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI). Copyright 2011 Wiley Periodicals, Inc. Catheterization and Cardiovascular Interventions 00:000–000 (2011)
The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Trancatheter aortic valve implantation for aortic stenosis. © National Institute for Health and Clinical Excellence, 2012. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.
The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Percutaneous laser coronary angioplasty. © National Institute for Health and Clinical Excellence, 2011. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.
The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on transcatheter endovascular closure of perimembranous ventricular septal defect . It replaces the previous guidance on Endovascular closure of perimembranous ventricular septal defect (Interventional Procedures Guidance no.172 May 2006). © National Institute for Health and Clinical Excellence, 2010. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.
The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. It replaces the previous guidance on Percutaneous occlusion of the left atrial appendage for atrial fibrillation, IPG181, June 2006. © National Institute for Health and Clinical Excellence, 2010. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.
The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Percutaneous closure of patent foramen ovale for recurrent migraine. © National Institute for Health and Clinical Excellence, 2010. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.
The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers. © National Institute for Health and Clinical Excellence, 2010. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.
Evidence on the safety and efficacy of percutaneous mitral valve leaflet repair for mitral regurgitation is currently inadequate in quality and quantity. Therefore, this procedure should only be used: • with special arrangements for clinical governance, consent and research for patients who are well enough for surgical mitral valve leaflet repair to treat their mitral regurgitation, or • in the context of research for patients who are not well enough for surgical mitral valve leaflet repair to treat their mitral regurgitation. Interventional procedure guidance 309. Copyright © National Institute for Health and Clinical Excellence, 2009. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.
Transcatheter aortic valve replacement (TAVR) offers new and potentially transformational technology for patients with severe aortic valvular stenosis who are either extremely high-risk candidates or inoperable for surgical aortic valve replacement (AVR) or who are inoperable by virtue of associated comorbidities. In the future, this technology may be utilized in lower risk surgical candidates. An estimated 40,000 patients have received TAVR worldwide. J. Am. Coll. Cardiol. 2012;59;1200-1254; originally published online Jan 31, 2012
Journal of the American College of Cardiology. Published online Nov 7, 2011. © 2011 by the American College of Cardiology Foundation; the American Heart Association, Inc. and the Society for Cardiovascular Angiography and Interventions
Journal of the American College of Cardiology. © 2011 by the American College of Cardiology Foundation and the Society of Thoracic Surgeons
Journal of the American College of Cardiology. © 2011 by the American College of Cardiology Foundation and the American Heart Association, Inc.
Journal of the American College of Cardiology. © 2007 by the European Society of Cardiology, the American College of Cardiology Foundation, the American Heart Association, and the World Heart Federation
Copyright © 2010 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539
Copyright © 2008 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos